[Expression of MiR-144/451 in Different Types of Anemia]

Fan Yang1, Ling Ling1, Ya-Yin Hou1

  • 1Yangzhou University School of Medicine, Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou 225009, Jiangsu Province, China.

Abstract

Insights

microRNA-144/451 (miR-144/451) levels differ in anemia types. Lower miR-144/451 expression was found in aplastic anemia and myelodysplastic syndrome, while miR-451 was higher in diffuse large B-cell lymphoma, suggesting diagnostic potential.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Context:

  • Anemia is a common hematological disorder with diverse causes.
  • MicroRNAs (miRNAs) play crucial roles in gene regulation and have been implicated in various diseases, including anemia.
  • The miR-144/451 gene cluster is known to be involved in erythropoiesis, but its role in different anemia types requires further investigation.

Purpose:

  • To investigate the expression levels of the miR-144/451 gene cluster in patients with aplastic anemia (AA), myelodysplastic syndrome (MDS), and diffuse large B-cell lymphoma (DLBCL)-related anemia.
  • To analyze the correlation between miR-144/451 expression and clinical laboratory parameters in these anemia types.

Summary:

  • Peripheral blood samples from newly diagnosed and post-chemotherapy patients with AA, MDS, and DLBCL were analyzed for miR-144 and miR-451 expression using RT-qPCR.
  • Significantly lower miR-144 and miR-451 expression was observed in AA and MDS patients compared to controls (P < 0.01).
  • DLBCL patients showed no significant difference in miR-144 expression but significantly higher miR-451 expression (P < 0.05) compared to controls. miR-144/451 expression positively correlated with RDW-CV in AA patients.

Impact:

  • This study reveals distinct expression patterns of miR-144/451 in different anemia types.
  • These findings suggest that miR-144 and miR-451 may serve as potential biomarkers for the diagnosis and differential diagnosis of clinical anemia.
  • Further research can explore the therapeutic potential of targeting miR-144/451 in specific anemia subtypes.